Tufik R Assad1, Bradley A Maron2,3, Ivan M Robbins1, Meng Xu4, Shi Huang4, Frank E Harrell4, Eric H Farber-Eger5, Quinn S Wells5,6, Gaurav Choudhary7,8, Anna R Hemnes1, Evan L Brittain5,6. 1. Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee. 2. Department of Medicine, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 3. Department of Cardiology, Boston VA Healthcare System, West Roxbury, Massachusetts. 4. Department of Biostatistics, Vanderbilt University, Nashville, Tennessee. 5. Vanderbilt Center for Translational and Clinical Cardiovascular Research, Vanderbilt University School of Medicine, Nashville, Tennessee. 6. Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee. 7. Vascular Research Laboratory, Providence VA Medical Center, Providence, Rhode Island. 8. Division of Cardiovascular Medicine, Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island.
Abstract
Importance: Pulmonary hypertension (PH) is diagnosed by a mean pulmonary arterial pressure (mPAP) value of at least 25 mm Hg during right heart catheterization (RHC). While several studies have demonstrated increased mortality in patients with mPAP less than that threshold, little is known about the natural history of borderline PH. Objective: To test the hypothesis that patients with borderline PH have decreased survival compared with patients with lower mPAP and frequently develop overt PH and to identify clinical correlates of borderline PH. Design, Setting, and Participants: Retrospective cohort study from 1998 to 2014 at Vanderbilt University Medical Center, comprising all patients undergoing routine RHC for clinical indication. We extracted demographics, clinical data, invasive hemodynamics, echocardiography, and vital status for all patients. Patients with mPAP values of 18 mm Hg or less, 19 to 24 mm Hg, and at least 25 mm Hg were classified as reference, borderline PH, and PH, respectively. Exposures: Mean pulmonary arterial pressure. Main Outcome and Measures: Our primary outcome was all-cause mortality after adjusting for clinically relevant covariates in a Cox proportional hazards model. Our secondary outcome was the diagnosis of overt PH in patients initially diagnosed with borderline PH. Both outcomes were determined prior to data analysis. Results: We identified 4343 patients (mean [SD] age, 59 [15] years, 51% women, and 86% white) among whom the prevalence of PH and borderline PH was 62% and 18%, respectively. Advanced age, features of the metabolic syndrome, and chronic heart and lung disease were independently associated with a higher likelihood of borderline PH compared with reference patients in a logistic regression model. After adjusting for 34 covariates in a Cox proportional hazards model, borderline PH was associated with increased mortality compared with reference patients (hazard ratio, 1.31; 95% CI, 1.04-1.65; P = .001). The hazard of death increased incrementally with higher mPAP, without an observed threshold. In the 70 patients with borderline PH who underwent a repeated RHC, 43 (61%) had developed overt PH, with a median increase in mPAP of 5 mm Hg (interquartile range, -1 to 11 mm Hg; P < .001). Conclusions and Relevance: Borderline PH is common in patients undergoing RHC and is associated with significant comorbidities, progression to overt PH, and decreased survival. Small increases in mPAP, even at values currently considered normal, are independently associated with increased mortality. Prospective studies are warranted to determine whether early intervention or closer monitoring improves clinical outcomes in these patients.
Importance: Pulmonary hypertension (PH) is diagnosed by a mean pulmonary arterial pressure (mPAP) value of at least 25 mm Hg during right heart catheterization (RHC). While several studies have demonstrated increased mortality in patients with mPAP less than that threshold, little is known about the natural history of borderline PH. Objective: To test the hypothesis that patients with borderline PH have decreased survival compared with patients with lower mPAP and frequently develop overt PH and to identify clinical correlates of borderline PH. Design, Setting, and Participants: Retrospective cohort study from 1998 to 2014 at Vanderbilt University Medical Center, comprising all patients undergoing routine RHC for clinical indication. We extracted demographics, clinical data, invasive hemodynamics, echocardiography, and vital status for all patients. Patients with mPAP values of 18 mm Hg or less, 19 to 24 mm Hg, and at least 25 mm Hg were classified as reference, borderline PH, and PH, respectively. Exposures: Mean pulmonary arterial pressure. Main Outcome and Measures: Our primary outcome was all-cause mortality after adjusting for clinically relevant covariates in a Cox proportional hazards model. Our secondary outcome was the diagnosis of overt PH in patients initially diagnosed with borderline PH. Both outcomes were determined prior to data analysis. Results: We identified 4343 patients (mean [SD] age, 59 [15] years, 51% women, and 86% white) among whom the prevalence of PH and borderline PH was 62% and 18%, respectively. Advanced age, features of the metabolic syndrome, and chronic heart and lung disease were independently associated with a higher likelihood of borderline PH compared with reference patients in a logistic regression model. After adjusting for 34 covariates in a Cox proportional hazards model, borderline PH was associated with increased mortality compared with reference patients (hazard ratio, 1.31; 95% CI, 1.04-1.65; P = .001). The hazard of death increased incrementally with higher mPAP, without an observed threshold. In the 70 patients with borderline PH who underwent a repeated RHC, 43 (61%) had developed overt PH, with a median increase in mPAP of 5 mm Hg (interquartile range, -1 to 11 mm Hg; P < .001). Conclusions and Relevance: Borderline PH is common in patients undergoing RHC and is associated with significant comorbidities, progression to overt PH, and decreased survival. Small increases in mPAP, even at values currently considered normal, are independently associated with increased mortality. Prospective studies are warranted to determine whether early intervention or closer monitoring improves clinical outcomes in these patients.
Authors: Gustavo A Heresi; Omar A Minai; Adriano R Tonelli; Jeffrey P Hammel; Samar Farha; Joseph G Parambil; Raed A Dweik Journal: Pulm Circ Date: 2013-12 Impact factor: 3.017
Authors: Marius M Hoeper; Harm Jan Bogaard; Robin Condliffe; Robert Frantz; Dinesh Khanna; Marcin Kurzyna; David Langleben; Alessandra Manes; Toru Satoh; Fernando Torres; Martin R Wilkins; David B Badesch Journal: J Am Coll Cardiol Date: 2013-12-24 Impact factor: 24.094
Authors: Bradley A Maron; Edward Hess; Thomas M Maddox; Alexander R Opotowsky; Ryan J Tedford; Tim Lahm; Karen E Joynt; Daniel J Kass; Thomas Stephens; Maggie A Stanislawski; Erik R Swenson; Ronald H Goldstein; Jane A Leopold; Roham T Zamanian; Jean M Elwing; Mary E Plomondon; Gary K Grunwald; Anna E Barón; John S Rumsfeld; Gaurav Choudhary Journal: Circulation Date: 2016-02-12 Impact factor: 29.690
Authors: Gabor Kovacs; Alexander Avian; Maria Tscherner; Vasile Foris; Gerhard Bachmaier; Andrea Olschewski; Horst Olschewski Journal: Chest Date: 2014-12 Impact factor: 9.410
Authors: S MacMahon; R Peto; J Cutler; R Collins; P Sorlie; J Neaton; R Abbott; J Godwin; A Dyer; J Stamler Journal: Lancet Date: 1990-03-31 Impact factor: 79.321
Authors: Tufik R Assad; Evan L Brittain; Quinn S Wells; Eric H Farber-Eger; Stephen J Halliday; Laura N Doss; Meng Xu; Li Wang; Frank E Harrell; Chang Yu; Ivan M Robbins; John H Newman; Anna R Hemnes Journal: Pulm Circ Date: 2016-09 Impact factor: 3.017
Authors: Scott H Visovatti; Oliver Distler; J Gerry Coghlan; Christopher P Denton; Ekkehard Grünig; Diana Bonderman; Ulf Müller-Ladner; Janet E Pope; Madelon C Vonk; James R Seibold; Juan-Vicente Torres-Martin; Martin Doelberg; Harbajan Chadha-Boreham; Daniel M Rosenberg; Vallerie V McLaughlin; Dinesh Khanna Journal: Arthritis Res Ther Date: 2014-12-10 Impact factor: 5.156
Authors: Kara N Goss; Arij G Beshish; Gregory P Barton; Kristin Haraldsdottir; Taylor S Levin; Laura H Tetri; Therese J Battiola; Ashley M Mulchrone; David F Pegelow; Mari Palta; Luke J Lamers; Andrew M Watson; Naomi C Chesler; Marlowe W Eldridge Journal: Am J Respir Crit Care Med Date: 2018-12-15 Impact factor: 21.405
Authors: Evan L Brittain; Thennapan Thennapan; Bradley A Maron; Stephen Y Chan; Eric D Austin; Edda Spiekerkoetter; Harm J Bogaard; Christophe Guignabert; Roxane Paulin; Roberto F Machado; Paul B Yu Journal: Am J Respir Crit Care Med Date: 2018-07-01 Impact factor: 21.405
Authors: Bernard Thébaud; Kara N Goss; Matthew Laughon; Jeffrey A Whitsett; Steven H Abman; Robin H Steinhorn; Judy L Aschner; Peter G Davis; Sharon A McGrath-Morrow; Roger F Soll; Alan H Jobe Journal: Nat Rev Dis Primers Date: 2019-11-14 Impact factor: 52.329
Authors: Anna R Hemnes; Alexander R Opotowsky; Tufik R Assad; Meng Xu; Laura N Doss; Eric Farber-Eger; Quinn S Wells; Evan L Brittain Journal: Chest Date: 2018-08-24 Impact factor: 9.410
Authors: Andres Mora Carpio; Aaron Goertz; Colleen Kelly; Leslee Willes; Stuart F Quan; Gregg S Pressman; Abesh Niroula; Sunil Sharma Journal: Int J Cardiovasc Imaging Date: 2020-11-19 Impact factor: 2.357
Authors: Bradley A Maron; Gabor Kovacs; Anjali Vaidya; Deepak L Bhatt; Rick A Nishimura; Susanna Mak; Marco Guazzi; Ryan J Tedford Journal: J Am Coll Cardiol Date: 2020-12-01 Impact factor: 24.094